ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO401

Development of a Fetal Kidney Failure Model through Nephron Progenitor Cell Ablation via the Intrinsic Apoptosis Pathway

Session Information

Category: Development, Stem Cells, and Regenerative Medicine

  • 600 Development, Stem Cells, and Regenerative Medicine

Authors

  • Matsui, Kenji, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Yamanaka, Shuichiro, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Matsumoto, Kei, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Yokoo, Takashi, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan

Group or Team Name

  • Div of Nephrology and Hypertension, Dept of Internal Medicine.
Background

Fetal organ failure models are promising for xenotransplantation targeting fetuses and developmental and pathological research. Conventional knockout models often result in fetal lethality, while tamoxifen-inducible conditional ablation models are harmful to fetuses and lack both rapidity and completeness. In this study, we introduce inducible caspase 9 (iC9) to mouse fetuses for the first time, creating a viable CKD model with an easily adjustable phenotype.

Methods

We developed Six2-iC9 mice that express iC9 in nephron progenitor cells (NPCs). To generate a congenital CKD model, we administered a chemical inducer of dimerization (CID) to pregnant mothers intraperitoneally, introducing NPC ablation in Six2-iC9+/+ offspring. This system's efficiency and speed of cell ablation were verified in the culture of Six2-iC9+/+ and Six2-iC9+/- fetal kidneys. Additionally, we developed loxP-iC9 mice and Six2-iC9 rats.

Results

A single intraperitoneal CID administration resulted in complete NPC ablation, with the severity adjustable depending on timing. Offspring treated at E13.5 survived, exhibiting significant increases in BUN and urinary albumin from as early as one month old. Histology demonstrated reduced glomeruli with compensatory hypertrophy, tubular dilation, and interstitial fibrosis. In whole-organ cultures of Six2-iC9+/+ fetal kidneys, NPC apoptosis began 6 hours after CID addition, with an ablation efficiency of 94%. Ablation was not induced in Six2-iC9+/-, confirming the existence of a threshold for iC9 expression. However, in dissociated and re-aggregated sphere cultures of Six2-iC9+/- kidneys, NPC ablation was achieved. RNA-seq suggested that DNA damage from cell dissociation made cells more susceptible to apoptosis. Even in whole-organ cultures, co-administering XIAP inhibitor with CID facilitated NPC ablation in Six2-iC9+/-. NPC ablation was also induced in loxP-iC9 mice crossed with Six2-Cre mice and in Six2-iC9 rats.

Conclusion

We established a congenital CKD model utilizing the intrinsic apoptosis pathway. Our findings indicate that iC9 expression levels and cell conditions influence this system's effectiveness. The successful implementation of the loxP system promises applications in other cell types, and the development of rat models will advance fetal xenotransplantation research.

Funding

  • Government Support – Non-U.S.